This World Mental Health Day 2026 (10 October), members of our Lived Experience Expert Panel (LEEP) share their experiences ...

Results from Stage 1 of the Octopus trial find one of the trial treatments, alpha lipoic acid, shows promise in progressive MS and will continue into trial Stage 2. Results from Stage 1 of Octopus, ...

The diverse conference program included presentations from experts in MS neurology, neuroimmunology, allied health, MS Nursing, men’s and women’s health and researchers, a selection of which are below ...

Australian researchers are growing ‘mini brains’ to help solve one of the biggest challenges in multiple sclerosis (MS) research – repairing damage caused by MS. The research, funded through MS ...

Each year, MS Australia holds two grant rounds to select only the top MS research projects to fund. Further information about the comprehensive grant review process is available here. The 19 new ...

Dr Carla Proietti is a researcher at the Institute for Molecular Bioscience at The University of Queensland. Driven by the excitement of discovery, Dr Proietti’s research is focused on understanding ...

In this episode of The Raw Nerve, Host Jeremy Henderson, Head of Advocacy for MS Australia, and Co-Host ⁠Sharlene Brown⁠, Chair of the MS Australia Awards Committee, spotlight the 2026 MS Australia ...

On Thursday 16 July, the Australian Government announced that Ocrevus and Kesimpta would remain on the Pharmaceutical Benefits Scheme (PBS). While the terms of reference for the review are still being ...

Thank you! Ocrevus and Kesimpta will remain on the PBS. Today is a great day for the MS community. The Australian Government has confirmed that Ocrevus and Kesimpta will remain available through the ...

MS Australia warmly welcomes the announcement from the Minister for Health and Aged Care, the Hon Mark Butler MP, that Ocrevus (ocrelizumab) and Kesimpta (ofatumumab) will remain available through the ...

Multiple disease-modifying therapies (DMTs), Ocrevus (ocrelizumab) and Kesimpta (ofatumumab), are at risk of being withdrawn from the Pharmaceutical Benefits Scheme (PBS), as a consequence of ...

An outcome measure used in MS to assess overall disease control. The most commonly used definition, known as NEDA‑3, is a composite measure indicating the absence of (1) clinical relapses, (2) ...